[{"orgOrder":0,"company":"Kither Biotech","sponsor":"Claris Ventures","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2022","type":"Series B Financing","leadProduct":"KIT2014","moa":"cAMP","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Kither Biotech","amount2":0.02,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"Inhalation","sponsorNew":"Kither Biotech \/ Claris Ventures","highestDevelopmentStatusID":"4","companyTruncated":"Kither Biotech \/ Claris Ventures"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"KIT2014","moa":"cAMP","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Preclinical","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Kither Biotech \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Kither Biotech \/ Not Applicable"},{"orgOrder":0,"company":"Kither Biotech","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Peptide","year":"2024","type":"Not Applicable","leadProduct":"KIT2014","moa":"","graph1":"Technology","graph2":"Approved","graph3":"Kither Biotech","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Technology","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"Kither Biotech \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Kither Biotech \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Kither Biotech

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : KIT2014 is a peptide-based therapy designed to inhibit PDE3/4, being investigated for the treatment of CF lung disease in adults.

                          Brand Name : KIT2014

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          October 30, 2024

                          Lead Product(s) : KIT2014

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : KIT2014, a novel, cell-permeable peptide that works to modulate cAMP levels inside cells, demonstrated a triple mechanism of action in reversing disease pathogenesis: enhancing functionality of CFTR channels and reducing bronchoconstriction and inflamma...

                          Brand Name : KIT2014

                          Molecule Type : Peptide

                          Upfront Cash : Not Applicable

                          March 31, 2022

                          Lead Product(s) : KIT2014

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Proceeds will be used to fund the clinical development of Kither’s lead product KIT2014, a novel cell- permeable peptide for the treatment of cystic fibrosis (CF) that works to modulate cyclic adenosine monophosphate (cAMP) levels inside cells.

                          Brand Name : KIT2014

                          Molecule Type : Peptide

                          Upfront Cash : Undisclosed

                          March 16, 2022

                          Lead Product(s) : KIT2014

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Claris Ventures

                          Deal Size : $18.5 million

                          Deal Type : Series B Financing

                          blank